Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07626528

Study of Wenyang Tongbi Formula in the Treatment of Chemotherapy-Induced Polyneuropathy

This clinical trial aims to evaluate the efficacy of Wenyang Tongbi Granules (a patented Traditional Chinese Medicine prescription) in treating chemotherapy-induced peripheral neuropathy (CIPN). The study compares Wenyang Tongbi Granules with mecobalamin tablets, a standard clinical medication, to determine whether the TCM intervention yields superior outcomes in sensory and motor function of the limbs, as well as overall systemic status, among patients presenting with paresthesia and pain during chemotherapy.

Methods: Participants who develop hand-foot paresthesia or pain during chemotherapy will receive either Wenyang Tongbi Granules or mecobalamin tablets daily for a continuous period of 42 days. Evaluations will be conducted on Day 1, Day 21, and Day 42. Outcome measures include the severity and duration of limb paresthesia, as well as changes in TCM-specific syndromes. Additionally, blood samples will be collected to assess variations in serum levels of multiple cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), before and after the intervention.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chemotherapy-induced Peripheral Neuropathy

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, 100021, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: Patients aged between 18 and 80 years (inclusive).
  • Life Expectancy: An anticipated survival time of ≥ 3 months.
  • Performance Status & Organ Function: A Karnofsky Performance Status (KPS) score ≥ 60 and adequate organ function.
  • Diagnosis: Histopathologically or cytologically confirmed breast cancer or colorectal cancer.
  • Chemotherapy Regimen: Currently undergoing chemotherapy containing taxanes or oxaliplatin.
  • Neurotoxicity Grade: Presence of Grade ≥ 2 peripheral neurotoxicity (according to NCI-CTCAE criteria) induced by chemotherapy.
  • TCM Syndrome Differentiation: Conforming to the "Yang Deficiency and Collateral Obstruction with Toxin-Stasis Accumulation Pattern" as defined in the Guidelines for Clinical Research of New Traditional Chinese Medicines.

Exclusion criteria

  • Allergy History: Known hypersensitivity to the active ingredients or excipients of the study drug/placebo; history of allergic constitution; or a history of allergies to ≥ 3 substances.
  • Comorbidities: Presence of severe psychiatric disorders; or pre-existing conditions such as diabetic neuropathy, hypothyroidism, renal insufficiency, radiculopathy, Charcot-Marie-Tooth disease, or Guillain-Barré syndrome.
  • Concomitant Medications: Use of Chinese patent medicines or herbal decoctions specifically for CIPN within 30 days prior to enrollment.
  • Compliance: Inability to adhere to the treatment protocol or difficulty in accurately assessing one's own general condition.
  • Pregnancy & Lactation: Pregnant or lactating women.

Treatment and study plan

Wenyang Tongbi Granules and Placebo mecobalamin

Drug

Placebo mecobalamin, one capsule per administration, three times daily (tid) with Wenyang Tongbi Granules (10 g/bag), administered as three bags per day for 42 consecutive days

Mecobalamin with placebo Wenyang Tongbi Granules

Drug

Mecobalamin (one capsule) administered three times daily (tid), combined with placebo Wenyang Tongbi Granules containing 5% of the original formula concentration (10 g/bag), administered as three bags per day for 42 consecutive days.

Primary outcomes

  1. Overall Response Rate (ORR)

    Time frame: At baseline (before treatment), Day 21, and Day 42.

    The evaluation was conducted with reference to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). The outcomes were classified into four categories: Complete Response (CR), Partial Response (PR), No Change (NC), and Progressive Disease (PD).

    The Overall Response Rate (ORR) was calculated as follows:

    ORR= Total number of cases Number of CR + PR cases

    ×100%

    Definitions:

    Complete Response (CR): Reduction of adverse event grade to Grade 1.

    Partial Response (PR): A decrease of at least one grade compared to baseline (pre-treatment).

    No Change (NC): No improvement in symptoms or signs; or minimal symptomatic improvement without corresponding sign improvement.

    Progressive Disease (PD): An increase of at least one grade compared to baseline (pre-treatment).

Secondary outcomes

  1. Improvement rate of EORTC Quality of Life - Chemotherapy-Induced Peripheral Neuropathy（EORTC QLQ-CIPN20）scores.

    Time frame: At baseline (before treatment), Day 21, and Day 42.

    The improvement rate was calculated using the formula:

    (Post-treatment score-Pre-treatment score×100%)/Pre-treatment score. This reflects the change in symptom burden and quality of life related to CIPN. The minimum value is 1 and maximum value is 4,the lower the better.

  2. Remission rate of neuropathic pain assessed by Douleur Neuropathique 4 questions(DN4).

    Time frame: At baseline (before treatment), Day 21, and Day 42.

    Pain remission was evaluated using the Douleur Neuropathique 4 questions (DN4)questionnaire. The remission rate was calculated as:

    (Pre-treatment score-Post-treatment score)/Pre-treatment score×100%.The minimum value is 1 and maximum value is 10,the lower the better.

  3. Reduction rate of TCM syndrome scores.

    Time frame: At baseline (before treatment), Day 21, and Day 42.

    According to the Guidelines for Clinical Research of New Traditional Chinese Medicines, the reduction rate was calculated based on the scoring criteria for "Yang Deficiency and Collateral Obstruction with Toxin-Stasis Accumulation Pattern".The minimum value is 1 and maximum value is 4,the lower the better.

  4. Numbness distribution and symptom severity scores.

    Time frame: At baseline (before treatment), Day 21, and Day 42.

    A novel supplementary rating scale was developed by our research group based on existing clinical scales and has been submitted for a national invention patent (Application No. 202511273259.8).The minimum value is 1 and maximum value is 10,the lower the better.

Study contacts

Contact information is provided by the study sponsor or research team.

YIN Yukun

CONTACT

[email protected]

010-87788030

Sponsors and collaborators

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Registry information

Official study title

A Multicenter Evidence-Based Clinical Study on the Safety and Efficacy of Wenyang Tongbi Formula in the Treatment of Chemotherapy-Induced Polyneuropathy

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jun 4, 2026
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.